Taxifolin alleviates podocyte injury and macrophage chemotaxis associated with diabetic nephropathy by directly targeting RBP1 identified via multi-omics and machine learning
- 1State Key Laboratory of Pharmaceutical Biotechnology, Department of Pharmacy, Nanjing Drum Tower Hospital, School of Life Sciences, Nanjing University, Nanjing, China
Abstract
Aims: Podocyte injury contributes to diabetic nephropathy (DN) progression. This study aimed to screen and validate the key functional proteins related to podocyte injury in DN, and to explore the protective effect of bioactive ingredients derived from traditional Chinese medicine Linggui Zhugan (LGZG) formula against DN.
Methods: Proteomics, weighted gene co-expression network analysis, machine learning, and repeated out-of-fold exact SHapley Additive exPlanations (TreeSHAP) analysis were integrated to screen the top 15 core differentially expressed proteins in kidney tissues of DN patients. Single-cell transcriptomics and cell-cell communication analysis were further used to identify the podocyte protein retinol-binding protein 1 (RBP1). In vitro, a palmitic acid (PA)-induced podocyte injury model and gene knockdown experiments were performed to verify the regulatory function of RBP1. Molecular docking and microscale thermophoresis (MST) were applied to screen and confirm the binding interaction between bioactive ingredients of LGZG formula and RBP1. The renoprotective effect of taxifolin was further evaluated in this cell model.
Results: Integrative multi-omics and machine learning identified RBP1 as a key pathogenic molecule in DN patients. In vitro, PA stimulation increased RBP1 protein expression in podocyte injury, with the downregulation of podocyte-specific slit diaphragm proteins nephrin and synaptopodin, and the upregulation of pro-inflammatory mediators including C-C motif chemokine ligand 2 (CCL2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), as well as enhanced macrophage chemotaxis. Notably, RBP1 knockdown reversed these PA-induced alterations to alleviate podocyte injury. Taxifolin from LGZG formula directly bound RBP1, as confirmed by molecular docking and MST. Furthermore, taxifolin was found to bind to RBP1. And then it suppressed nuclear factor κB (NF-κB) signaling pathway, reduced CCL2, IL-6 and TNF-α mRNA expression, inhibited macrophage chemotaxis, and upregulated nephrin and synaptopodin expression, thereby ameliorating PA-induced podocyte injury.
Conclusion: This study identified RBP1 as a novel driver of podocyte injury and macrophage chemotaxis associated with DN via multi-omics and machine learning. Taxifolin, a bioactive compound from the LGZG formula, directly bound to RBP1 and alleviated podocyte injury. These findings highlight RBP1 as a promising therapeutic target and support the potential of taxifolin as a targeted intervention for DN progression.
Related
- Resveratrol alleviates glucolipid metabolism disorders in diabetic nephropathy via the HIF-1α pathway: a network pharmacology and experimental validation study
- Itaconate as the endogenous brake of proinflammatory macrophage activation alleviates inflammation in liver fibrogenesis.
- ScRNA‐Seq Reveals Jiangfu Zhixie Formula Alleviates IBS‐D by Inhibiting Macrophage M1 Polarization through HIF‐1α‐Glycolysis Axis
- Triple Renal Pathology in a Patient With Myeloperoxidase-Associated Vasculitis, Diabetic Nephropathy, and Immunoglobulin A Nephropathy: A Case Report
- LncRNA ZFPM2 silencing alleviates lung epithelial injury by inducing M2 macrophage polarization: possible implication in bronchopulmonary dysplasia.
BibTeX
@article{wang2026taxifolin,
title = {{Taxifolin alleviates podocyte injury and macrophage chemotaxis associated with diabetic nephropathy by directly targeting RBP1 identified via multi-omics and machine learning}},
author = {Zi-Xuan Wang and Wen-Xuan Wang and Qiong-Dan Liang and Ling-Dong Kong},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1933167},
url = {https://doi.org/10.3389/fphar.2026.1933167},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Taxifolin alleviates podocyte injury and macrophage chemotaxis associated with diabetic nephropathy by directly targeting RBP1 identified via multi-omics and machine learning
AU - Zi-Xuan Wang
AU - Wen-Xuan Wang
AU - Qiong-Dan Liang
AU - Ling-Dong Kong
PY - 2026
DA - 2026/10/12
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1933167
UR - https://doi.org/10.3389/fphar.2026.1933167
AB - Aims: Podocyte injury contributes to diabetic nephropathy (DN) progression. This study aimed to screen and validate the key functional proteins related to podocyte injury in DN, and to explore the protective effect of bioactive ingredients derived from traditional Chinese medicine Linggui Zhugan (LGZG) formula against DN. Methods: Proteomics, weighted gene co-expression network analysis, machine learning, and repeated out-of-fold exact SHapley Additive exPlanations (TreeSHAP) analysis were integrated to screen the top 15 core differentially expressed proteins in kidney tissues of DN patients. Single-cell transcriptomics and cell-cell communication analysis were further used to identify the podocyte protein retinol-binding protein 1 (RBP1). In vitro, a palmitic acid (PA)-induced podocyte injury model and gene knockdown experiments were performed to verify the regulatory function of RBP1. Molecular docking and microscale thermophoresis (MST) were applied to screen and confirm the binding interaction between bioactive ingredients of LGZG formula and RBP1. The renoprotective effect of taxifolin was further evaluated in this cell model. Results: Integrative multi-omics and machine learning identified RBP1 as a key pathogenic molecule in DN patients. In vitro, PA stimulation increased RBP1 protein expression in podocyte injury, with the downregulation of podocyte-specific slit diaphragm proteins nephrin and synaptopodin, and the upregulation of pro-inflammatory mediators including C-C motif chemokine ligand 2 (CCL2), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), as well as enhanced macrophage chemotaxis. Notably, RBP1 knockdown reversed these PA-induced alterations to alleviate podocyte injury. Taxifolin from LGZG formula directly bound RBP1, as confirmed by molecular docking and MST. Furthermore, taxifolin was found to bind to RBP1. And then it suppressed nuclear factor κB (NF-κB) signaling pathway, reduced CCL2, IL-6 and TNF-α mRNA expression, inhibited macrophage chemotaxis, and upregulated nephrin and synaptopodin expression, thereby ameliorating PA-induced podocyte injury. Conclusion: This study identified RBP1 as a novel driver of podocyte injury and macrophage chemotaxis associated with DN via multi-omics and machine learning. Taxifolin, a bioactive compound from the LGZG formula, directly bound to RBP1 and alleviated podocyte injury. These findings highlight RBP1 as a promising therapeutic target and support the potential of taxifolin as a targeted intervention for DN progression.
SN - 1663-9812
ER -